Predictive Value of Initial PET-SUVmax in Patients with Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma

Introduction: We have previously shown that in early clinical stage esophageal adenocarcinoma, a positron emission tomography standardized uptake values (PET SUVmax) of <4.5 is associated with earlier pathologic stage and predicts better survival. In this study, we analyze the impact of the pretreatment PET SUVmax in patients with locally advanced esophageal adenocarcinoma who undergo preoperative chemoradiotherapy. Methods: We performed a retrospective analysis, selecting patients with adenocarcinoma of the esophagus who had a pretreatment PET scan and who received chemoradiotherapy before esophagectomy. Data recorded included demographics, PET SUVmax, treatment details, pathologic details, and survival data. Comparison of categorical variables was done by &khgr;2 analysis, continuous variables by t test, survival analysis by the Kaplan-Meier method, and comparisons of survival using the log-rank test. Results: Between January 1996 and September 2007, 189 patients were appropriate for this analysis. The initial PET SUVmax was <4.5 in 28 patients and ≥4.5 in 161 patients. The two groups were similar with regards to demographics and treatment details. Patients in the low SUV group were less likely to show evidence of treatment response after chemoradiotherapy, including a higher likelihood of residual nodal disease and a lower likelihood of a pathologic complete response and estimated treatment response. However, both groups had similar survival. Conclusions: Although the initial PET SUVmax does not predict survival in patients with locally advanced esophageal adenocarcinoma who receive preoperative chemoradiotherapy, patients with a high initial SUVmax respond better to preoperative therapy. These results can be used to better select esophageal cancer patients for combined modality treatment.

[1]  R. Boellaard,et al.  18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome , 2008, Journal of Cancer Research and Clinical Oncology.

[2]  Weiguang Wang,et al.  Decreased [18F]fluoro-2-deoxy-d-glucose incorporation and increased glucose transport are associated with resistance to 5FU in MCF7 cells in vitro. , 2007, Nuclear medicine and biology.

[3]  Wolfgang A Weber,et al.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. , 2007, The Lancet. Oncology.

[4]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[5]  V. Rusch,et al.  The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. , 2007, The Journal of thoracic and cardiovascular surgery.

[6]  V. Rusch,et al.  American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Y. Bang,et al.  High Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Advanced Non–Small Cell Lung Cancer on Platinum-Based Combination Chemotherapy , 2006, Clinical Cancer Research.

[8]  Y. Nishiyama,et al.  Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  R. Cerfolio,et al.  Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. , 2004, The Annals of thoracic surgery.

[10]  S. Larson,et al.  Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Wolfgang A Weber,et al.  Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Torsten Mattfeldt,et al.  Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  M. Schwaiger,et al.  Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Larson,et al.  Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Buchert,et al.  In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  U. Cremerius,et al.  Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma , 2001, Nuklearmedizin.

[17]  K. Bland,et al.  Preoperative 18[F]-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values Predict Survival After Esophageal Adenocarcinoma ResectionRizk N, Downey RJ, Akhurst T, et al (Mem Sloan-Kettering Cancer Ctr) Ann Thorac Surg 81:1076–1082, 2006§ , 2007 .

[18]  Rodney J Hicks,et al.  Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  Yukiko Arisaka,et al.  18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.